Combination preparation, containing cyclosporin a or FK506 or rapamycin and a xanthine derivative

US6432968B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Martin Schönharting · Taunusstein, DE
• Ulrich Gebert · Königstein, DE
• Mark Waer · Heverlee, BE

Key dates

• Filing date: Nov 10, 1999
• Grant date: Aug 13, 2002
• Expiry date: Nov 10, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Xanthines of the formula I are useful in producing a superadditive increase in immunosuppressive action when combined with immunosuppressive compounds such as CysA or FK506.